0000950138-17-000150.txt : 20170210 0000950138-17-000150.hdr.sgml : 20170210 20170210191743 ACCESSION NUMBER: 0000950138-17-000150 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170203 FILED AS OF DATE: 20170210 DATE AS OF CHANGE: 20170210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Stereotaxis, Inc. CENTRAL INDEX KEY: 0001289340 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943120386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4320 FOREST PARK AVENUE STREET 2: SUITE 100 CITY: ST.LOUIS STATE: MO ZIP: 63108 BUSINESS PHONE: 314-678-6100 MAIL ADDRESS: STREET 1: 4320 FOREST PARK AVENUE STREET 2: SUITE 100 CITY: ST.LOUIS STATE: MO ZIP: 63108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fischel Nathan CENTRAL INDEX KEY: 0001389932 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36159 FILM NUMBER: 17595267 MAIL ADDRESS: STREET 1: 10990 WILSHIRE BOULEVARD STREET 2: SUITE 1400 CITY: LOS ANGELES STATE: CA ZIP: 90024 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2017-02-03 0 0001289340 Stereotaxis, Inc. STXS 0001389932 Fischel Nathan C/O STEREOTAXIS, INC. 4320 FOREST PARK AVENUE, SUITE 100 ST. LOUIS MO 63108 1 0 0 0 Common Stock 1372862 I See footnote Series A Convertible Preferred Stock .65 Common Stock 12558567 I See footnote Common Stock Warrant (right to buy) .70 2016-09-29 2021-09-29 Common Stock 12307692 I See footnote Common Stock Warrant (right to buy) 3.361 2013-08-07 2018-11-11 Common Stock 1041357 I See footnote Held by funds of which DAFNA Capital Management, LLC, a Delaware limited liability company, is the investment manager and general partner. Dr. Fischel is the Chief Executive Officer, of DAFNA Capital Management, LLC. The Series A convertible preferred stock is convertible at the election of the holder at any time and has no expiration date. The number of shares is based on the initial conversion price of $.65. The conversion price is subject to adjustment. For purposes of determining the number of shares of common stock upon conversion, the value of the convertible preferred stock will be increased by the amount of dividends at a rate of 6% per annum, which will be cumulative and accrue daily from the date of issuance on the $1,000 stated value. The conversion of the Series A convertible preferred stock, and exercising of the warrants are restricted to the extent that, upon such conversion or exercise, the number of shares of common stock then beneficially owned by the holder of such securities and its affiliates would exceed 4.99% of the total number of shares of common stock then outstanding. Initial conversion/exercise price. The conversion/exercise price is subject to adjustment. The number of shares is based on the initial exercise price of $.70. The exercise price is subject to adjustment. The conversion of the Series A convertible preferred stock, and exercising of the warrants are restricted to the extent that, upon such conversion or exercise, the number of shares of common stock then beneficially owned by the holder of such securities and its affiliates would exceed 4.99% of the total number of shares of common stock then outstanding. /s/ Karen W. Duros, Attorney-in-Fact 2017-02-09